Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Angiogenesis and Tumor Microenvironment Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EGFL7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EGFL7 Recombinant Protein (HEK293 Expressed) High purity (>95%), Endotoxin controlled (<1 EU/ug). Sequence Verified. Correct native glycosylation. |
View EGFL7 Products |
| Gene Delivery | EGFL7 Promise-ORF / Lentivirus Full-length ORF sequence for stable cell line generation and functional assays. |
View EGFL7 Products |
| Benchmark Ab | Anti-EGFL7 Recombinant Antibody Recombinant positive control derived from Parsatuzumab sequence. |
View EGFL7 Products |
| Validator | EGFL7 siRNA Set Target-specific knockdown verification in endothelial cell assays. |
View EGFL7 Products |
| Related Target A | VEGFA Synergistic angiogenic target; key partner for combination therapy studies and resistance bypass. |
View VEGFA Products |
| Related Target B | NOTCH1 Downstream pathway receptor; EGFL7 regulates Notch signaling to control vascular branching. |
View NOTCH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, mouse, and cynomolgus EGFL7 ortholog proteins available with >95% purity |
| Subfamily counter screening | Related EGF-like domain-containing proteins strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Parsatuzumab biosimilar) included |
| False Positives | Validated siRNA sets included for target specificity verification |
Live EGFL7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EGFL7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination regimens and multi-specific constructs. As first-generation therapies reach the clinic, the next wave of R&D is targeting anti-VEGF resistance pathways and tumor vascular normalization.
EGFL7 (Epidermal Growth Factor-Like Domain-Containing Protein 7) is a secreted angiogenic factor highly expressed in remodeling vasculature and various solid tumors. Historically validated by Roche/Genentech's Parsatuzumab, modern drug discovery has repositioned EGFL7 not as a standalone target, but as a critical synergistic hub. Inhibiting EGFL7 disrupts the vascular scaffolding, rendering endothelial cells highly sensitive to anti-VEGF therapies and immune checkpoint inhibitors. Current strategies focus on bispecific antibodies targeting both EGFL7 and VEGFA, as well as novel antibody-drug conjugates (ADCs) designed to selectively destroy tumor-associated endothelial cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Genentech (Roche), Academic Institutions | Colorectal Cancer, NSCLC, Solid Tumors | Ligand-blocking assays (Requires highly pure, natively folded EGFL7 protein) |
| Bispecific / Multi-specific | Biotech Innovators | Refractory Wet AMD, Oncology | Simultaneous binding kinetics (Requires precise human/cyno ortholog proteins) |
| Combination Therapy | Clinical Sponsors | Anti-VEGF Resistant Tumors | Synergy validation panels (Requires VEGFA and NOTCH1 pathway components) |